Detalhe da pesquisa
1.
Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.
J Hepatol
; 67(5): 999-1008, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28687477
2.
Predicting the risk of venous thromboembolism in patients hospitalized with heart failure.
Circulation
; 130(5): 410-8, 2014 Jul 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-24970782
3.
Corrigendum to "Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies" [J hepatol 67 (2017) 999-1008].
J Hepatol
; 69(4): 990-991, 2018 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-30104026
4.
Extended Thromboprophylaxis in Hospitalized Patients with Heart Failure: A Post Hoc Analysis of the MAGELLAN Study.
TH Open
; 6(4): e304-e308, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36299620
5.
Cancer-Associated ThrOmboSIs - Patient-Reported OutcoMes With RivarOxaban (COSIMO) - Baseline characteristics and clinical outcomes.
Res Pract Thromb Haemost
; 5(8): e12604, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34877446
6.
Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients.
J Am Heart Assoc
; 10(5): e019459, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33586478
7.
Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis.
TH Open
; 4(1): e59-e65, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-32190813
8.
Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials.
Thromb Haemost
; 120(3): 515-524, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-31975354
9.
Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION Trial.
Thyroid
; 29(12): 1820-1827, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31860408
10.
Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study.
Clin Appl Thromb Hemost
; 25: 1076029619886022, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31746218
11.
Patient-reported outcomes associated with changing to rivaroxaban for the treatment of cancer-associated venous thromboembolism - The COSIMO study.
Thromb Res
; 206: 1-4, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34332213